SHARE:  
Join Our Email List
  
CRGC News Broadcast
NB-2019-021
October 3, 2019
New Field Testing Opportunity Available

The NAACCR Mid-Level Tactical Group, (MLTG) which includes representations from all standard setters (CoC, NAACCR, NCRA, NPCR, and SEER/IMS) now requires that field testing be done for proposed new data items, or major changes, before implementation in the registry field.  

This process will help standard setters to evaluate the feasibility of collecting new data items and clarify codes and coding instructions before implementation. The MLTG strongly encourages participation in this effort, which we believe will facilitate better communication with the registrars in the field and provide critical information to the groups working on these data items.

The Field Test will be implemented using the same software used for SEER Reliability Studies, with some modifications. Participation in the Field Test will not be required by any of the standard setters, but is strongly encouraged. This is your chance to comment on data items prior to implementation. This is the first time a field test like this has been done, and based on how well it goes, this could become standard operations for implementation of proposed new data items. 

There are 12 new SSDIs that are being proposed for implementation in 2021.
 
·        Breast and Colon: Treatment Effect (Primary Tumor)
·        Breast: Treatment Effect (Lymph Nodes)
·        Colon and Rectum: NRAS Mutational Analysis
·        Colon and Rectum: BRAF Mutational Analysis
·        Lung: EGRF Mutational Analysis
·        Lung: ALK Rearrangement by Molecular Methods
·        Pancreas: CA 19-9 Pre Tx-Lab Value
·        Neuroendocrine Tumors: Ki-67 (Ampulla of Vater, Appendix, Colon and Rectum, Pancreas, Small Intestine, Stomach)
·        Corpus Carcinoma and Carcinosarcoma: ER and PR
·        Esophagus and Stomach: HER2 Overall Summary

Each of these SSDIs has clinical significance for their cancers. The field testing will provide information to the NAACCR SSDI workgroup for
  • Clarification of codes and coding instructions
  • Needed revisions and/or modifications
  • How often the information is available
  • Feasibility of implementing the new SSDI
In addition to new SSDIs being tested, there will also be testing on changes to how the registry collects Neoadjuvant therapy. These changes will include a new data item that asks, "was neoadjuvant therapy given." This new data item will provide clear instructions on what is neoadjuvant therapy, along with codes determining if patient had neoadjuvant therapy or not.

The field testing will take place from 5 a.m. Pacific, November 1, 2019 to 9:00 p.m. Pacific, December 15, 2019. Participants must have access to the SEER reliability studies site (https://reliability.seer.cancer.gov) during this period. Registration for Field Testing will open on Tuesday, October 15, 2019.   Continuing Education Units (CEU's) will be offered.

Registrars can impact future data collection by participating, offering feedback and obtain CEU's! 

For further information click here. 
If you have questions or concerns regarding any of the content of this CRGC News Broadcast please contact me .   

Mignon Dryden, CTR
Director, E-Reporting
Cancer Registry of Greater California